FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200459441> ?p ?o ?g. }

• W4200459441 endingPage "S716" @default.
• W4200459441 startingPage "S715" @default.
• W4200459441 abstract "Abstract Background Tebipenem (TBP) is an oral carbapenem in clinical development for treating complicated urinary tract infections (UTIs), including pyelonephritis. This study investigates the epidemiology of E. coli (EC) causing UTI in U.S. patients and the activity of TBP and comparators against various subsets. Methods A total of 2,395 EC recovered from urine samples during the 2018-2020 STEWARD Surveillance Program were included. Isolates were collected from medical centers in all 9 US Census Regions and centrally tested by reference broth microdilution method. MIC interpretation was based on CLSI criteria. Isolates that met MIC criteria were subjected to genome sequencing, followed by screening of extended-spectrum β-lactamase (ESBL) genes and epidemiology typing (MLST). Results A total of 16.1%, 15.4% and 14.6% of EC met the ESBL screening criteria in 2018, 2019 and 2020, respectively. 269/360 (74.7%) carried blaCTX-M and 2/360 (0.6%) had blaSHV-12. blaCMY (33/360; 9.2%) was the most common cephalosporinase, followed by blaDHA (7/360; 1.9%). A CRE phenotype was noted in 1 isolate from New York, which carried blaKPC-2. Acquired genes were not detected in 56 strains. 50 ST types were noted in isolates that met the ESBL criteria screening, with the majority of isolates being ST131 (56.2%). 21 (6.7%) and 19 (6.0%) isolates belonged to ST38 and ST1193, respectively, followed by STs represented by 8 or less isolates. Among ST131, 56.5% carried blaCTX-M from group 1 and 35.6% had genes associated with group 9. Overall, TBP showed consistent MIC50 values throughout the subsets. ERT had activity (≥97.0% susceptible) against the various subsets; however, lower susceptibility rates (85.7-90.6%) were noted against isolates carrying plasmid AmpC. Other agents (ceftriaxone and cefazolin) had activity only against non-ESBL producers. Conclusion bla CTX-M comprised the majority of acquired genes detected among ESBL strains, which belonged mostly to ST131, emphasizing the expansion of this clone. TBP showed consistent activity against all subsets, regardless of resistance genotype or lineage. These data support the clinical development of TBP as a convenient oral treatment option for UTI caused by EC. Disclosures Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Timothy B. Doyle, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Ian A. Critchley, Ph.D., Spero Therapeutics (Employee, Shareholder) Nicole Cotroneo, Spero Therapeutics (Employee, Shareholder) Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support" @default.
• W4200459441 created "2021-12-31" @default.
• W4200459441 creator A5014992940 @default.
• W4200459441 creator A5041157580 @default.
• W4200459441 creator A5042729483 @default.
• W4200459441 creator A5045551151 @default.
• W4200459441 creator A5055309597 @default.
• W4200459441 creator A5063814702 @default.
• W4200459441 date "2021-11-01" @default.
• W4200459441 modified "2023-10-16" @default.
• W4200459441 title "1254. Molecular Epidemiology of Escherichia coli Causing Urinary Tract Infections in United States and in vitro Activity of Tebipenem, Including Against Strain Lineage and Resistant subsets (2018-2020)" @default.
• W4200459441 doi "https://doi.org/10.1093/ofid/ofab466.1446" @default.
• W4200459441 hasPublicationYear "2021" @default.
• W4200459441 type Work @default.
• W4200459441 citedByCount "0" @default.
• W4200459441 crossrefType "journal-article" @default.
• W4200459441 hasAuthorship W4200459441A5014992940 @default.
• W4200459441 hasAuthorship W4200459441A5041157580 @default.
• W4200459441 hasAuthorship W4200459441A5042729483 @default.
• W4200459441 hasAuthorship W4200459441A5045551151 @default.
• W4200459441 hasAuthorship W4200459441A5055309597 @default.
• W4200459441 hasAuthorship W4200459441A5063814702 @default.
• W4200459441 hasBestOaLocation W42004594411 @default.
• W4200459441 hasConcept C104317684 @default.
• W4200459441 hasConcept C107130276 @default.
• W4200459441 hasConcept C126322002 @default.
• W4200459441 hasConcept C135763542 @default.
• W4200459441 hasConcept C2776817793 @default.
• W4200459441 hasConcept C2778022156 @default.
• W4200459441 hasConcept C54355233 @default.
• W4200459441 hasConcept C547475151 @default.
• W4200459441 hasConcept C71924100 @default.
• W4200459441 hasConcept C77411442 @default.
• W4200459441 hasConcept C86803240 @default.
• W4200459441 hasConcept C89423630 @default.
• W4200459441 hasConcept C97669555 @default.
• W4200459441 hasConceptScore W4200459441C104317684 @default.
• W4200459441 hasConceptScore W4200459441C107130276 @default.
• W4200459441 hasConceptScore W4200459441C126322002 @default.
• W4200459441 hasConceptScore W4200459441C135763542 @default.
• W4200459441 hasConceptScore W4200459441C2776817793 @default.
• W4200459441 hasConceptScore W4200459441C2778022156 @default.
• W4200459441 hasConceptScore W4200459441C54355233 @default.
• W4200459441 hasConceptScore W4200459441C547475151 @default.
• W4200459441 hasConceptScore W4200459441C71924100 @default.
• W4200459441 hasConceptScore W4200459441C77411442 @default.
• W4200459441 hasConceptScore W4200459441C86803240 @default.
• W4200459441 hasConceptScore W4200459441C89423630 @default.
• W4200459441 hasConceptScore W4200459441C97669555 @default.
• W4200459441 hasIssue "Supplement_1" @default.
• W4200459441 hasLocation W42004594411 @default.
• W4200459441 hasLocation W42004594412 @default.
• W4200459441 hasOpenAccess W4200459441 @default.
• W4200459441 hasPrimaryLocation W42004594411 @default.
• W4200459441 hasRelatedWork W2141764281 @default.
• W4200459441 hasRelatedWork W2312194719 @default.
• W4200459441 hasRelatedWork W2342146826 @default.
• W4200459441 hasRelatedWork W2359817556 @default.
• W4200459441 hasRelatedWork W2371759661 @default.
• W4200459441 hasRelatedWork W2412574627 @default.
• W4200459441 hasRelatedWork W2414680297 @default.
• W4200459441 hasRelatedWork W2792561364 @default.
• W4200459441 hasRelatedWork W3144733943 @default.
• W4200459441 hasRelatedWork W4288392727 @default.
• W4200459441 hasVolume "8" @default.
• W4200459441 isParatext "false" @default.
• W4200459441 isRetracted "false" @default.
• W4200459441 workType "article" @default.